MissionIR News - Escalon Medical Partners With Modernizing Medicine, Inc. To Offer Integrated EMR Image Management

Integrated system will provide complete patient management from a single merged solution

Atlanta, GA (PRWEB) - MissionIR would like to highlight Escalon Medical Corp., a publicly traded company that operates in the healthcare market specializing in the development, manufacture, marketing, and distribution of medical devices for use in ophthalmology. The company owns subsidiary companies that are branded and operate together as Sonomed Escalon. The Sonomed Escalon group is a leader in ophthalmic diagnostics imaging, providing ultrasound, digital photography, and image management systems. Sonomed, Inc. and Escalon Medical Imaging are wholly-owned subsidiaries of Escalon Medical Corp. The company seeks to grow its ophthalmic business by focusing on its existing products, developing new products, utilizing strategic partnerships, and through acquisition.

In the company’s news last week,

Escalon Medical announced that its Sonomed Escalon group has partnered with Modernizing Medicine to supply cloud-based, end-to-end electronic medical records (EMR) and image management solutions for ophthalmic practices.

Seamlessly integrating Sonomed Escalon’s AXIS image management software with Modernizing Medicine’s Electronic Medical Assistant EMA Ophthalmology EMR solution will provide complete patient management from a single merged solution – from coding and prescribing at the touch of a button to powerful exam image review tools and more. The integrated solutions will be introduced by the two companies at the American Academy of Ophthalmology’s annual meeting, scheduled to take place Nov. 10-13 in Chicago, Ill.

Due to its power, flexibility, ease of use, and focus on improving clinical efficiency, EMA Ophthalmology is a cloud-enabled EMR that is quickly becoming one of the leading solutions in the industry. The partnering of these two entities will now add to this solution unmatched exam image review capabilities and complete integration with almost any diagnostic imaging device.

Because both Sonomed Escalon and Modernizing Medicine have shown a commitment to creating accessible mobile offerings – particularly on the iPad platform – the two companies will make ideal partners. With the addition of AXIS’s cutting-edge integration of diagnostic images to patient records stored in EMA, doctors will now save even more time. With the newly combined AXIS EMA Ophthalmology solution, ophthalmologists will now be able to review diagnostic images – such as OCT, fluorescein angiography, color fundus, and others – and then interpret the exam results directly on an iPad.

The partnership will further allow Escalon and Modernizing Medicine to offer their individual products as either standalone solutions or an integrated package.

Escalon Medical is engaged in the development and distribution of ophthalmologic diagnostic and surgical products. The company is focused on utilizing strategic partnerships to bolster its development programs and is also seeking acquisitions to further expand its product offerings. Escalon Medical is headquartered in Wayne, Penn., and also has operations in New York, Wisconsin, and Massachusetts.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.